RhoJ Regulates Melanoma Chemoresistance by Suppressing Pathways That Sense DNA Damage
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Melanomas resist conventional chemotherapeutics, in part, through intrinsic disrespect of apoptotic checkpoint activation. In this study, using an unbiased genome-wide RNA interference screen, we identified RhoJ and its effector PAK1, as key modulators of melanoma cell sensitivity to DNA damage. We find that RhoJ activates PAK1 in response to drug-induced DNA damage, which then uncouples ATR from its downstream effectors, ultimately resulting in a blunted DNA damage response (DDR). In addition, ATR suppression leads to the decreased phosphorylation of ATF2 and consequent increased expression of the melanocyte survival gene Sox10 resulting in a higher DDR threshold required to engage melanoma cell death. In the setting of normal melanocyte behavior, this regulatory relationship may facilitate appropriate epidermal melanization in response to UV-induced DNA damage. However, pathologic pathway activation during oncogenic transformation produces a tumor that is intrinsically resistant to chemotherapy and has the propensity to accumulate additional mutations. These findings identify DNA damage agents and pharmacologic inhibitors of RhoJ/PAK1 as novel synergistic agents that can be used to treat melanomas that are resistant to conventional chemotherapies. Cancer Res; 72(21); 5516–28. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627 · cited 1×
“Synthetic-lethal screening has been used to identify genes that regulate lung cancer, cervical cancer, and breast cancer chemoresistance (9-11).”
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548 · cited 1×
“Transcriptional (6) and enzymatic regulators of melanogenesis (7) also modulate melanoma chemoresponsiveness.”
MITF: master regulator of melanocyte development and melanoma oncogene
Levy, C., Khaled, M., & Fisher, D. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.008 · Cited by 1,169 · cited 1×
“ATR suppression in turn leads to the increased expression of Sox10, which can in turn regulate MITF, a transcription factor that controls the expression of multiple genes required for melanin production (46).”
Melanoma genome sequencing reveals frequent PREX2 mutations
Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., Ivanova, E., Watson, I. R., Nickerson, E., Ghosh, P., et al. (2012) · Nature · doi:10.1038/nature11071 · Cited by 756
Peschiaroli, A., Dorrello, N. V., Guardavaccaro, D., Venere, M., Halazonetis, T., Sherman, N. E., & Pagano, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.013 · Cited by 289
Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma
Shakhova, O., Zingg, D., Schaefer, S. M., Hari, L., Civenni, G., Blunschi, J., Claudinot, S., Okoniewski, M., Beermann, F., Mihic-Probst, D., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2535 · Cited by 274
Abdel-Malek, Z. A., Kadekaro, A. L., & Swope, V. B. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00679.x · Cited by 134
ATR and H2AX cooperate in maintaining genome stability under replication stress
Chanoux, R. A., Yin, B., Urtishak, K. A., Asare, A., Bassing, C. H., & Brown, E. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806739200 · Cited by 130
Cited by
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
“For instance, Ho et al.(277) found that the GTPase”
BackgroundG-quadruplexes: a promising target for cancer therapy
Kosiol, N., Juranek, S., Brossart, P., Heine, A., & Paeschke, K. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01328-4 · Cited by 533
Bélanger, F., Rajotte, V., & Drobetsky, E. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085294 · Cited by 29
“Interestingly one recent report showed that the CDC42 homologue RhoJ and its effector PAK1 modulate ATR activity via degradation of claspin after DNA damage thereby uncoupling ATR from Chk1; moreover RhoJ appears to be upregulated in advanced melanoma [49].”
BackgroundStructure-based design of CDC42 effector interaction inhibitors for the treatment of cancer
Jahid, S., Ortega, J. A., Vuong, L. M., Acquistapace, I. M., Hachey, S. J., Flesher, J. L., La Serra, M. A., Brindani, N., La Sala, G., Manigrasso, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110641 · Cited by 21
Self-citation
Metadata
- Authors
- Ho, H., Aruri, J., Kapadia, R., Mehr, H., White, M. A., & Ganesan, A. K.
- Venue
- Cancer Research
- Published
- 2012-10-31
- Volume
- 72
- Issue
- 21
- Pages
- 5516-5528
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2164456343
- Cited by
- 64
- References
- 8
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RhoJ Regulates Melanoma Chemoresistance by Suppressing Pathways That Sense DNA Damage. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-0775
- The paper
- Ho, H., Aruri, J., Kapadia, R., Mehr, H., White, M. A., & Ganesan, A. K. (2012). RhoJ Regulates Melanoma Chemoresistance by Suppressing Pathways That Sense DNA Damage. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-0775
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.